

Biocon Biologics launches interchangeable biosimilars SEMGLEE and Insulin Glargine injection in US

16 November 2021 | News

Branded and unbranded versions of the first-ever interchangeable biosimilar in the US provide more affordable options for the millions of Americans living with diabetes



Biocon Biologics, a subsidiary of Biocon, and Viatris Inc have announced the US launch of interchangeable biosimilars SEMGLEE[®] (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

Both biosimilar products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, $LANTUS^{\textcircled{\tiny{8}}}$ (insulin glargine), allowing for substitution at the pharmacy counter.

Shreehas Tambe, Deputy CEO, Biocon Biologics said: "At Biocon Biologics we are committed to expanding access to high-quality, affordable biologics to patients worldwide. The launch of our interchangeable biosimilar insulin glargine in the U.S. by our partner Viatris is in line with our aspiration to provide our biosimilar insulins to 'one in five' insulin dependent people with diabetes, globally. This is indeed a landmark event and along with the recent formulary listings, we believe it will allow us to improve accessibility, availability and adoption of biosimilars in the U.S. for the benefit of patients and the overall healthcare system."